2020 Clinical practice guidelines for Chronic heart failu

Russian Journal of Cardiology
25, 4083
DOI: 10.15829/1560-4071-2020-4083

Citation Report

#	Article	IF	Citations
1	Position of Patients with Mid-Range Ejection Fraction in the General Chronic Heart Failure Population. Russian Archives of Internal Medicine, 2021, 11, 111-121.	0.2	2
2	Carbohydrate metabolism disorders in patients with heart failure: data from the local registry. Russian Journal of Cardiology, 2021, 26, 4330.	1.4	3
3	Experience of remote monitoring of patients with cardiovascular diseases in the Perm Krai. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2838.	1.4	3
6	Socio-economic impact of heart failure in Russia. Russian Journal of Cardiology, 2021, 26, 4490.	1.4	19
7	Impact of obesity on echocardiographic parameters and N-terminal pro-brain natriuretic peptide levels in patients with heart failure with mid-range ejection fraction: unanswered questions. Russian Journal of Cardiology, 2021, 26, 4462.	1.4	0
9	Improving outpatient care in chronic heart failure. Kuban Scientific Medical Bulletin, 2021, 28, 14-24.	0.4	1
10	Left ventricular myocardial cellular perfusion against the background of cardiac contractility modulation in patients with heart failure and atrial fibrillation. Russian Journal of Cardiology, 2021, 26, 4238.	1.4	0
11	Clinical traits of chronic heart failure in patients with arterial hypertension and senile asthenia syndrome: an observational cross-sectional study. Kuban Scientific Medical Bulletin, 2021, 28, 25-40.	0.4	1
13	Four-year follow-up of a patient with mixed cardiomyopathy and an implanted cardiac contractility modulation device: a case report. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2811.	1.4	1
14	Evidence born from ASCOT trial â€“ still important after 15 years. Eurasian Heart Journal, 2021, , 46-53.	0.8	1
18	Assessment of prevalence and monitoring of outcomes in patients with heart failure in Russia. Russian Journal of Cardiology, 2020, 25, 4204.	1.4	7
19	Types of hemodynamic response to orthostasis according to continuous blood pressure monitoring: a case series of heart failure with reduced ejection fraction. Russian Journal of Cardiology, 2021, 26, 4574.	1.4	0
20	Rehabilitation after COVID-19. Resolution of the International Expert Council of the Eurasian Association of Therapists and the Russian Society of Cardiology. Russian Journal of Cardiology, 2021, 26, 4694.	1.4	9
21	Ð¡onsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardiology, 2021, 26, 4703.	1.4	36
22	Biomarkers ST2 and interleukin 33 for assessing the severity of cardiac inflammation and fibrosis in patients with chronic heart failure. Russian Journal of Cardiology, 2021, 26, 4530.	1.4	2
23	Role of catestatin in development and decompensation of heart failure: a literature review. Russian Journal of Cardiology, 2021, 26, 4492.	1.4	2
24	Diagnostic value of electrocardiographic markers of left bundle branch block in predicting left ventricular reverse remodeling in patients receiving cardiac resynchronization therapy. Russian Journal of Cardiology, 2021, 26, 4500.	1.4	2
25	ICD-10 code-based definition of heart failure in Saint Petersburg electronic health records: prevalence, health care utilization and outcomes. Russian Journal of Cardiology, 2021, 26, 4621.	1.4	4

#	Article	IF	Citations
26	Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases. Russian Journal of Cardiology, 2020, 25, 4142.	1.4	3
27	Heart failure in coronary artery disease: review of medical certificates of cause of death. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 3039.	1.4	1
28	Influence of viscersal obesity and adipokin status on the rsenal function in hyperstensive patients with obesity and chrsonic hearst failurse. Nephrology (Saint-Petersburg), 2021, 25, 39-48.	0.4	0
29	Polymorbidity and indicators of carbohydrate, lipid and purine metabolism in patients with arterial hypertension. The Siberian Scientific Medical Journal, 2021, 41, 48-53.	0.3	1
31	The Modern Aspects of Nutrition during Chronic Heart Failure. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2022, , 62-73.	0.4	0
32	Effect of salt intake on clinical course and hemodynamics in patients with hypertrophic cardiomyopathy. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 2889.	1.4	0
33	Patients with a Combination of Atrial Fibrillation and Chronic Heart Failure in Clinical Practice: Comorbidities, Drug Treatment and Outcomes. Rational Pharmacotherapy in Cardiology, 2022, 17, 816-824.	0.8	1
35	Acetazolamide in the Cheyneâ€"Stokes Respiration Therapy in Patients with Chronic Heart Failure: A Pilot Randomized Study. Human Physiology, 2022, 48, 78-85.	0.4	1
36	Risk of heart failure depending on the state of renal filtration function in patients with uncomplicated hypertension. Russian Journal of Cardiology, 2022, 27, 4859.	1.4	0
37	Comprehensive physical rehabilitation of patients with heart failure: impact on clinical and functional status and analysis of problems related to the enrollment. Russian Journal of Cardiology, 2022, 27, 4814.	1.4	0
38	Comparison of classifications and justification of the need for transdisciplinary consensus to take into account the prevalence and mortality associated with chronic heart failure. Complex Issues of Cardiovascular Diseases, 2022, 11, 6-16.	0.5	2
39	Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part II. Russian Journal of Cardiology, 2022, 27, 4759.	1.4	3
40	Risk factors and diagnostic value of urinary N-terminal pro-brain natriuretic peptide for verification of heart failure in human immunodeficiency virus-infected patients. Russian Journal of Cardiology, 2022, 27, 4853.	1.4	0
41	Prediction of Adverse Post-Infarction Left Ventricular Remodeling Using a Multivariate Regression Model. Diagnostics, 2022, 12, 770.	2.6	3
42	Pro-inflammatory cytokines in chronic cardiac failure: state of problem. Terapevticheskii Arkhiv, 2021, 93, 1389-1394.	0.8	7
43	Reverse remodeling against the background of cardiac contractility modulation therapy in patients with heart failure and atrial fibrillation. Cardiovascular Therapy and Prevention (Russian) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	1.4	
44	Analysis of the compliance of the prescribed therapy with the EURO FORTA system in polymorbidic patients of elderly and old age with CHF. Kardiologiya, 2021, 61, 57-64.	0.7	1
45	Treatment strategies for patients with atrial fibrillation and chronic heart failure. Terapevticheskii Arkhiv, 2021, 93, 1545-1550.	0.8	1

#	Article	IF	Citations
47	Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure. Russian Journal of Cardiology, 2022, 26, 4800.	1.4	2
48	Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts. Russian Journal of Cardiology, 2022, 26, 4791.	1.4	1
49	Proteomic Studies of Blood and Vascular Wall in Atherosclerosis. International Journal of Molecular Sciences, 2021, 22, 13267.	4.1	9
50	Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial. Terapevticheskii Arkhiv, 2021, 93, 1491-1497.	0.8	6
52	Acute decompensated heart failure. What has changed in the clinical guidelines in 2021?. Consilium Medicum, 2022, 24, 7-12.	0.3	0
53	Chronic heart failure â€“ modification of treatment paradigm. Consilium Medicum, 2022, 24, 13-19.	0.3	1
54	Contribution of the COVID-19 pandemic to the prognosis of patients with class III-IV heart failure. Russian Journal of Cardiology, 2022, 27, 4842.	1.4	2
55	Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial. Russian Journal of Cardiology, 2022, 27, 4945.	1.4	1
57	Drug-induced pulmonary artery hypertension. Kachestvennaya Klinicheskaya Praktika, 2022, , 53-63.	0.5	1
58	Antiarrhythmic and Hemodynamic Effects of Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Diseases. Rational Pharmacotherapy in Cardiology, 2022, 18, 209-217.	0.8	1
59	Prediction of cerebrovascular complications of coronary artery bypass grafting in patients without significant stenosis of the carotid arteries. Russian Neurological Journal, 2022, 27, 34-42.	0.3	0
61	The role of cardiac biomarkers and epicardial fat in the diagnosis of heart failure in patients with various types of atrial fibrillation. Russian Journal of Cardiology, 2022, 27, 4882.	1.4	1
62	Optimization of intravascular volume determination in patients with acute decompensated heart failure. Russian Journal of Cardiology, 2022, 27, 5039.	1.4	1
63	Prevention of complications in the treatment of chronic heart failure in 2022: results of a survey of specialists. Profilakticheskaya Meditsina, 2022, 25, 33.	0.6	0
64	Treatment of iron deficiency in patients after acute decompensation: a new target in the treatment of heart failure. Russian Journal of Cardiology, 2022, 27, 4949.	1.4	3
65	Physiciansâ€™ adherence to the guidelines on the chronic heart failure diagnosis and treatment. Kardiologiya, 2022, 62, 53-61.	0.7	3
66	Development and implementation of a heart failure telemonitoring system: the single centre experience. Kardiologiya, 2022, 62, 45-52.	0.7	1
67	Iron deficiency in Russia heart failure patients. Observational cross-sectional multicenter study. Kardiologiya, 2022, 62, 4-8.	0.7	3

#	Article	IF	Citations
68	Endpoints: types, selection, interpretation of the results obtained on the example of cardiology studies. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 3243.	1.4	1
69	Predictive potential of blood biomarkers for subsequent ventricular tachyarrhythmias in patients with chronic heart failure and reduced left ventricular ejection fraction: review. Journal of Arrhythmology, 2022, 29, 58-69.	0.2	1
70	Cognitive and emotional disorders in patients with chronic heart failure: prospects for detection and correction. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2022, 14, 87-93.	1.2	6
71	Role of ergoreflex activity in the pathogenesis of heart failure. The effectiveness of physical rehabilitation. Russian Journal of Cardiology, 2022, 27, 4937.	1.4	1
72	Chronic and acute decompensated heart failure: topical issues. Complex Issues of Cardiovascular Diseases, 2022, 11, 184-195.	0.5	3
73	Assessment of the Clinical Profile and Approaches to the Diagnosis and Treatment of Patients Hospitalized with Acute Decompensation of Heart Failure. I P Pavlov Russian Medical Biological Herald, 2022, 30, .	0.5	1
74	Heart failure and osteoporosis: common pathogenetic components. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 3233.	1.4	3
75	Results of pilot remote monitoring of heart failure patients. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 3151.	1.4	0
76	Advantages of long-term combination pharmacotherapy with a beta-blocker and eplerenone in patients with ST-segment elevation acute coronary syndrome. Cardiovascular Therapy and Prevention (Russian) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.4	2
77	Left atrial function in patients with heart failure. Cardiovascular Therapy and Prevention (Russian) Tj ETQq1 1 0.784314 rgBT /Overlock	1.4	2
78	Current guidelines for Î²-adrenoblockers use in cardiovascular diseases: focus on metoprolol succinate CR/XL: A review. Cardiosomatics, 2022, 13, 51-62.	0.4	1
79	Prognostic value of hypoxia-inducible factor-1 alpha gene polymorphism in patients with heart failure with preserved ejection fraction and obstructive sleep apnea. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 3276.	1.4	0
80	To the question of the main of acute urinary retention development during myocardial infarction in young and middle-aged men predictors. IzvestiÃ¢ Rossijskoj Voenno-medicinskoj Akademii, 2022, 41, 175-186.	0.2	0
81	Algorithm for the management of patients with ventricular arrhythmias recorded during wakefulness. Russian Journal of Cardiology, 2022, 27, 5048.	1.4	0
82	Prevalence and clinical associations of iron deficiency in patients with decompensated heart failure, depending on the diagnostic criteria used for iron deficiency. Terapevticheskii Arkhiv, 2022, 94, 844-849.	0.8	0
83	Heart failure and atrial fibrillation: updates and perspectives. Russian Journal of Cardiology, 2022, 27, 5018.	1.4	1
84	Hormonal characteristics of androgen status and their relationship with the anthropometric and metabolic parameter in men depending on the severity of hypertension. Acta Biomedica Scientifica, 2022, 7, 52-61.	0.2	0
85	Cardiovascular disease and cognitive impairment. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 7.	0.7	2

#	Article	IF	Citations
86	Clinical portrait of a patient with chronic heart failure and its outpatient management in the Moscow region. Medical Technologies Assessment and Choice (ÐœÐµÐ´Ð¸Ñ†Ð¸Ð½ÑÐºÐ¸Ðµ Ñ‚ÐµÑ…Ð½Ð¾Ð»Ð¾Ð³Ð¸Ð¸ ÐžÑ†ÐµÐ½ÐºÐ°	0.4	0
87	Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction In Patients With Resistant Hypertension and Type 2 Diabetes Mellitus. Kardiologiya, 2022, 62, 11-18.	0.7	0
88	Remote monitoring of outpatients discharged from the emergency cardiac care department. Russian Journal of Cardiology, 2022, 27, 5072.	1.4	0
89	Assessment of cognitive disorders in fragile patients with arterial hypertension and chronic heart failure. Ã›Å¾no-Rossijskij Å¾urnal TerapevtiÄeskoj Praktiki, 2022, 3, 32-40.	0.3	0
90	Prognostic value of left ventricular global longitudinal strain and mechanical dispersion by speckle tracking echocardiography in patients with ischemic and nonischemic cardiomyopathy: a systematic review and meta-analysis. Russian Journal of Cardiology, 2022, 27, 5034.	1.4	1
91	Functional Status And Cytokine Profile Assessment In Patients With Chronic Obstructive Pulmonary Disease And Chronic Heart Failure. Russian Open Medical Journal, 2022, 11, .	0.3	0
92	The Prognostic Value of Neuregulin-1Î² in Heart Failure Patients With Preserved Ejection Fraction. Kardiologiya, 2022, 62, 3-8.	0.7	2
93	New principles for the treatment of chronic heart failure: the phenomenon of sodium-glucose cotransporter type 2 inhibitors. Meditsinskiy Sovet, 2022, , 44-51.	0.5	0
94	The effectiveness of cardiac contractility modulation in patients with chronic heart failure and atrial fibrillation: results of the 12-month follow-up. Terapevticheskii Arkhiv, 2022, 94, 1078-1084.	0.8	1
95	Comprehensive assessment of cardiovascular complications in a patient with type 1 diabetes mellitus, chronic kidney disease and diabetic neuroosteoarthropathy. AlÊ¹manah KliniÄeskoj Mediciny, 2022, 50, 205-215.	0.3	0
96	Acute decompensation of heart failure: state of the problem. Terapevticheskii Arkhiv, 2022, 94, 1047-1051.	0.8	3
97	Hyporesponse to statin therapy among patients with acute coronary syndrome: prevalence, impact on the development of heart failure in a short-term follow-up. Russian Journal of Cardiology, 2022, 27, 5001.	1.4	0
98	Effect of spironolactone therapy on the activity of the matrix metalloproteinase system in patients with heart failure after COVID-19. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 3431.	1.4	0
99	Insulin-like Growth Factor-1 and Myocardial Remodeling in Patients with Chronic Heart Failure of Ischemic Origin. Rational Pharmacotherapy in Cardiology, 2022, 18, 564-570.	0.8	0
100	The influence of atrial fibrillation on the prognostic value of brain natriuretic peptide (BNP) in risk assesment of paroxysmal ventricular tachycardia. , 2022, 21, 51-57.	0.2	0
101	Subclinical left ventricular dysfunction and N-terminal pro-brain natriuretic peptide in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya, 2022, 60, 560-565.	1.0	1
102	The Role of Structured Telephone Support in the Development of Self-care in Comorbid Patients with Chronic Heart Failure. Rational Pharmacotherapy in Cardiology, 2022, 18, 510-515.	0.8	0
103	THE CLINICAL SIGNIFICANCE OF EVALUATIONARTERIAL STIFFNESS IN PATIENTS WITH CHRONIC HEART FAILURE AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE. , 2022, 19, 64-70.		0

#	Article	IF	Citations
104	Prognostic significance of geometric patterns of left ventricular hypertrophy in a 12-year cohort study. Arterial Hypertension (Russian Federation), 2022, 28, 532-545.	0.4	0
105	Cardiac contractility modulation in heart failure with reduced ejection fraction treatment. Kardiologiya, 2022, 62, 71-78.	0.7	1
106	Factors Associated with a Positive Hemodynamic Response to Cardiac Resynchronization Therapy. , 2022, 2, 39-48.		0
107	Ten-year survival and clinical biochemical status of nonprogressors and responders to cardiac resynchronization therapy. Journal of Arrhythmology, 2022, 29, 7-16.	0.2	0
108	Heart failure with preserved left ventricular ejection fraction amidst diabetes mellitus: from general mechanisms to possible therapy tactics. Cardiosomatics, 2022, 13, 115-123.	0.4	0
109	Features of vascular rigidity in patients with arterial hypertension in combination with chronic heart failure and senile asthenia syndrome. Arterial Hypertension (Russian Federation), 2023, 28, 659-668.	0.4	0
110	Insulin resistance and heart failure with preserved ejection fraction. Pathogenetic and therapeutic crossroads. Diabetes Mellitus, 2023, 25, 535-547.	1.9	0
111	Long-term outcomes in patients with an implanted cardioverter-defibrillator according to the Kuzbass registry. Kardiologiya, 2022, 62, 57-63.	0.7	0
112	Potential new application points of SGLT2 inhibitors in patients with heart failure in combination with diabetes mellitus, non-alcoholic fatty liver disease and anemia (literature review). The Siberian Scientific Medical Journal, 2022, 42, 4-14.	0.3	1
113	The Effect of COVID-19 on Long-Term Cardiac Function in Patients With Chronic Heart Failure. Kardiologiya, 2022, 62, 23-29.	0.7	0
114	Significance of standard and speckle-tracking echocardiography for early diagnosis of asymptomatic left ventricular dysfunction in type 2 diabetes. Cardiovascular Therapy and Prevention (Russian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 33		
115	Sleep-related breathing disorders in patients with heart failure with reduced and mildly reduced ejection fraction: main types and their dependence on heart failure etiology. Russian Journal of Cardiology, 2023, 28, 5261.	1.4	0
116	Problematic aspects of iron deficiency compensation in heart failure. Russian Journal of Cardiology, 2023, 28, 5103.	1.4	0
117	Twenty-four-year-old patient with heart failure after myocarditis. Results of quadruple therapy: a case report. Russian Journal of Cardiology, 2023, 28, 5341.	1.4	0
118	Ð¡ost-effectiveness of preventing cardiovascular death and achieving the target indicator "Reduction of the cardiovascular mortality of the population" of the State Program "Health Development" when using valsartan+sacubitril, dapagliflozin and empagliflozin in patients with heart failure with reduced ejection fraction. Russian Journal of Cardiology, 2023, 28, 5386.	1.4	4
119	Evidence-based perspective on heart failure and osteoporosis: a systematic review. Russian Journal of Cardiology, 2023, 28, 5306.	1.4	1
120	Characteristics of anemia in heart failure: iron metabolism, erythropoietic activity and markers of inflammation. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3332.	1.4	0
121	Risk factors for development of the post-COVID syndrome. Klinicist, 2023, 16, 19-26.	0.5	1

#	Article	IF	Citations
122	Classification of heart failure: focus on prevention. Russian Journal of Cardiology, 2023, 28, .	1.4	2
123	Diastolic dysfunction in late postmenopausal patients with undifferentiated connective tissue disease and hypertension. Russian Journal of Cardiology, 2023, 28, 5151.	1.4	0
124	Influence of intravenous ferric carboxymaltose on non-invasive parameters of left ventricular myocardial work in patients with heart failure with reduced ejection fraction. Russian Journal of Cardiology, 2023, 28, 5310.	1.4	1
125	Assessment of the Myocardial Stress Biomarker NT-proBNP in Real Clinical Practice. Obshchaya Reanimatologiya, 2023, 19, 4-12.	1.0	6
127	Sacubitril/valsartan as a component of therapy for chronic heart failure. Reviews on Clinical Pharmacology and Drug Therapy, 2023, 20, 407-413.	0.6	0
128	Prognostic value of N-terminal Brain Natriuretic Peptide (NT-proBNP) in Risk Assessment of Adverse Cardiovascular Events in Patients with Atrial Fibrillation and Heart Failure with Reduced Left Ventricular Systolic Function. , 2023, 2, 5-15.		0
129	Risk Assessment of Adverse Outcomes in Symptomatic Patients With Arterial Hypertension and Chronic Heart Failure With Preserved Ejection Fraction Using THE HFA-PEFF Algorithm. Kardiologiya, 2023, 63, 3-10.	0.7	0
130	Cardiovascular effects of omega-3 polyunsaturated fatty acids: position of omega-3 polyunsaturated fatty acids in Russian and international guidelines. Council of Experts. Kardiologiya, 2023, 63, 11-18.	0.7	0
131	Factors associated with iron deficiency in heart failure. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3367.	1.4	0
132	Life expectancy in patients with chronic heart failure, atrial fibrillation and implantable cardiac contractility modulation devices. Kardiologicheskii Vestnik, 2023, 18, 38.	0.4	0
133	Clinical characteristics and frequency of anticoagulation in patients with atrial fibrillation and heart failure: results of a retrospective big data analysis. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3477.	1.4	2
134	. The moderated ct angiography of the heart scanning protocol for children with dilated cardiomyopathy. , 2023, 3, 18-26.		0
135	Diastolic dysfunction of the left and right ventricles in patients with calcium pyrophosphate crystal deposition disease and osteoarthritis. Nauchno-Prakticheskaya Revmatologiya, 2023, 61, 112-119.	1.0	0
136	Assessment Of Fluid Retention In Patients With Paroxysmal And Long-Standing Persistent Types Of Atrial Fibrillation. Russian Open Medical Journal, 2023, 12, .	0.3	0
137	Cardiovascular Diseases and Cognitive Impairments. Neuroscience and Behavioral Physiology, 2023, 53, 186-192.	0.4	1
138	Iron deficiency states in cardiovascular diseases: impact on prognosis and features of correction. Ã›Å¾no-Rossijskij Å¾urnal TerapevtiÄeskoj Praktiki, 2023, 4, 7-18.	0.3	0
139	A study of the digital readiness of patients with chronic heart failure. Profilakticheskaya Meditsina, 2023, 26, 101.	0.6	1
140	Analysis of mortality among patients suffering from heart failure, using the example of a megalopolis. Vestnik of Russian Military Medical Academy, 2023, 25, 85-94.	0.3	0

#	Article	IF	Citations
141	The role of the renin-angiotensin-aldosterone system in the development of cardiovascular complications in COVID-19. Pediatrician (St Petersburg), 2023, 14, 98-118.	0.3	0
142	Pharmacotherapy of heart failure with reduced ejection fraction: heart failure basic therapy and an episode of decompensation. Kardiologiya, 2023, 63, 66-76.	0.7	1
143	Hypertensive heart: from left ventricular hypertrophy to chronic heart failure. Arterial Hypertension (Russian Federation), 2023, 29, 138-149.	0.4	0
144	Prevalence and characteristics of newly diagnosed heart failure in patients with shortness of breath after coronavirus infection. Russian Journal of Cardiology, 2023, 28, 5385.	1.4	1
145	Practical aspects of vericiguat therapy in patients with heart failure with reduced ejection fraction. Expert council resolution. Russian Journal of Cardiology, 2023, 28, 5423.	1.4	1
146	Clinical Efficacy and Safety of Empagliflozin in Patients with Acute Heart Failure from the First Day of Hospitalization. Rational Pharmacotherapy in Cardiology, 2023, 19, 126-133.	0.8	0
147	The first results of advanced medical care for chronic heart failure in different regions of the Russian Federation. Kardiologicheskii Vestnik, 2023, 18, 29.	0.4	1
148	Metabolic syndrome components and vitamin D availability relationship in late postmenopausal women. Obesity and Metabolism, 2023, 20, 4-12.	1.2	0
149	Predictive accuracy of cardiac risk indices for cardiovascular complications in patients undergoing noncardiac surgery. Innovative Medicine of Kuban, 2023, , 5-12.	0.2	0
150	Organizing medical care for patients with chronic heart failure in Russia regions with a low population density. Profilakticheskaya Meditsina, 2023, 26, 102.	0.6	0
151	Comparison of International Guidelines for Managing Chronic Heart Failure with Reduced Ejection Fraction. Current Problems in Cardiology, 2023, 48, 101867.	2.4	1
152	Prognostic significance of the biomarker NT-proBNP in the surgical treatment of aortic stenosis (pilot study). Messenger of Anesthesiology and Resuscitation, 2023, 20, 6-19.	0.6	1
153	Diagnostic challenges of heart failure with preserved ejection fraction: focus on echocardiography. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3565.	1.4	1
154	Interstitial Edema of the Interatrial Septum in Patients with Atrial Fibrillation and Chronic Heart Failure. Bulletin of Experimental Biology and Medicine, 2023, 174, 711-715.	0.8	0
155	The HFA-PEFF diagnostic algorithm for diagnosing heart failure with preserved ejection fraction in hypertensive patients. Arterial Hypertension (Russian Federation), 2023, 29, 211-219.	0.4	0
156	Prognostic value of echocardiographic parameters of cardiac remodeling in patients with hypertension and obstructive sleep apnea. Arterial Hypertension (Russian Federation), 2023, 29, 164-174.	0.4	1
157	Cardiac resynchronization therapy: potential for arrhythmic risk modification. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3555.	1.4	0
158	Clinical characteristics and factors associated with death from acute decompensated heart failure. Journal of Arrhythmology, 2023, 30, 35-43.	0.2	1

#	Article	IF	Citations
159	Analysis of the information about the incidence of heart failure, associated mortality and burden on the healthcare system, based on the encoding data in 15 subjects of the Russian Federation. Russian Journal of Cardiology, 2023, 28, 5339.	1.4	1
160	Genetic factors of heart failure (review). Sibirskij Å¾urnal KliniÄeskoj I Ã¨ksperimentalÊ¹noj Mediciny, 2023, 38, 38-43.	0.4	1
161	Clinical and economic analysis of empagliflozin therapy in patients with heart failure across the ejection fraction range. Russian Journal of Cardiology, 2023, 28, 5475.	1.4	0
162	Prognostic significance of NT-proBNP and sST2 biomarkers in patients with post-myocardial infarction heart failure after a coronavirus infection. Russian Journal of Cardiology, 2023, 28, 5216.	1.4	0
163	Relationships and Activities. The study is supported by OOO AstraZeneca PharÂmaceuticals.. Russian Journal of Cardiology, 2023, 28, 5456.	1.4	2
164	A screening method for predicting left ventricular dysfunction based on spectral analysis of a single-channel electrocardiogram using machine learning algorithms. Biomedical Signal Processing and Control, 2023, 86, 105219.	5.7	0
165	Associations of elevated levels of brain natriuretic peptide and heart failure and their contribution to survival in the Russian middle-aged population: data from the ESSE-RF study. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3553.	1.4	1
166	Quality of life and adherence to therapy in patients with chronic heart failure who were remotely monitored by chatbot compared to the standard follow-up group for 3 months. Digital Diagnostics, 2023, 4, 53-56.	0.6	0
167	Ventricular tachycardia and myocardial infarction during antiarrhythmic therapy: a case report. Rational Pharmacotherapy in Cardiology, 2023, 19, 264-269.	0.8	1
168	Heart failure with improved ejection fraction in patients with tachycardia-induced cardiomyopathy: a case report. Rational Pharmacotherapy in Cardiology, 2023, 19, 270-276.	0.8	0
170	Comorbidity of chronic heart failure and osteoporosis: literature review. Cardiosomatics, 2023, 14, 93-104.	0.4	0
171	Assessment and modification of cardiovascular risk in non-cardiac surgery. Clinical guidelines 2023. Russian Journal of Cardiology, 2023, 28, 5555.	1.4	1
172	Peculiarities of hemodynamic assessment in patients with centrifugal circulatory assist system. Kardiologicheskii Vestnik, 2023, 18, 6.	0.4	0
173	Relationship between parameters of myocardial electrical remodeling and parameters of contractile function, deformation and myocardium work in patients with chronic heart failure with low left ventricular ejection fraction and atrial fibrillation. Kardiologiya, 2023, 63, 14-20.	0.7	0
174	Cardio-oncology today: digest of the first European clinical guidelines (2022). Kardiologiya, 2023, 63, 3-15.	0.7	0
175	Guidance letter for cardiologists of oncology institutions on the prevention of cardiovascular complications of anticancer therapy. Interdisciplinary Council of Cardio-Oncology, Russian Society of Cardiology. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3685.	1.4	0
176	Guidance letter for cardiologists and primary care physicians on primary prevention of cardiovascular complications of anticancer therapy. Interdisciplinary Council of Cardio-Oncology, Russian Society of Cardiology. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3684.	1.4	0
177	Features of phenotyping patients with heart failure with preserved ejection fraction. Russian Journal of Cardiology, 2023, 28, 5348.	1.4	0

#	Article	IF	Citations
178	Efficacy and safety of acetazolamide in patients with NYHA class II-IV decompensated heart failure: protocol of an open-label prospective randomized multicenter study (ORION-A). Russian Journal of Cardiology, 2023, 28, 5477.	1.4	0
179	Assessment of disturbed functions in patients with chronic heart failure using International classification of functioning ICF categories. Medical and Social Expert Evaluation and Rehabilitation, 2023, 25, 211-218.	0.2	0
180	Prevalence and clinical significance of iron deficiency in patients with acute decompensated heart failure. Russian Journal of Cardiology, 2023, 28, 5413.	1.4	0
181	New possibilities of pathogenetic correction of anemia in chronic heart failure. Klinicheskaia Meditsina, 2023, 101, 387-394.	0.1	0
182	Codiotoxicity of anthraciclines and the possibilities of its correction. Ã›Å¾no-Rossijskij Å¾urnal TerapevtiÄeskoj Praktiki, 2023, 4, 7-14.	0.3	0
183	ECHOCARDIOGRAPHIC PREDICTORS OF ADVERSE CLINICAL EVENTS IN HEART FAILURE WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION IN COMBINATION WITH OBSTRUCTIVE SLEEP APNEA. Complex Issues of Cardiovascular Diseases, 2023, 12, 161-172.	0.5	0
184	New phenotype of a patient with heart failure and Â«supra-normal left ventricular ejection fractionÂ». Kardiologicheskii Vestnik, 2023, 18, 16.	0.4	0
185	ÐÐ¸ÑÐºÐ¸ ÑÐµÑ€Ð´ÐµÑ‡Ð½Ð¾-ÑÐ¾ÑÑƒÐ´Ð¸ÑÑ‚Ñ‹Ñ… ÑÐ¾Ð±Ñ‹Ñ‚Ð¸Ð¹ Ñƒ Ð¿Ð°Ñ†Ð¸ÐµÐ½Ñ‚Ð¾Ð² Ñ•Ñ…ÐµÑ€Ð¾Ð¹ Ð½Ð¾Ñ€Ð¼Ð°Ð»ÑŒÐ½Ð¾Ð¹		
186	ÐÐ°Ð·Ð²Ð¸Ñ‚Ð¸Ðµ ÑÐ¼ÐµÑ€Ñ‚ÐµÐ»ÑŒÐ½Ñ‹Ñ… ÑÐµÑ€Ð´ÐµÑ‡Ð½Ð¾-ÑÐ¾ÑÑƒÐ´Ð¸ÑÑ‚Ñ‹Ñ… ÑÐ¾Ð±Ñ‹Ñ‚Ð¸Ð¹ Ñƒ Ð¿Ð°Ñ†Ð¸ÐµÐ½Ñ‚Ð¾Ð²Ð½		
187	Ð”Ð²Ð° Ð¼ÐµÑ‚Ð¾Ð´Ð° Ð¾Ñ€Ñ€ÐµÐºÑ†Ð¸Ð¸Ð½Ñ•ÐµÐ´Ð¾ÑÑ‚Ð°Ñ‚Ð¾Ñ‡Ð½Ð¾ÑÑ‚Ð¸ NT-proBNP, Ð¿Ð¾Ð»ÑƒÑ‡ÐµÐ½Ð½Ñ‹Ñ…		
188	Prognostic significance of NT-proBNP and sST2 in patients with heart failure with preserved and mildly reduced ejection fraction. Rational Pharmacotherapy in Cardiology, 2023, 19, 310-319.	0.8	0
189	Biomarkers in predicting mortality from cardiovascular events in patients with heart failure and an implanted cardioverter-defibrillator. Rational Pharmacotherapy in Cardiology, 2023, 19, 359-366.	0.8	0
190	Iron deficiency anemia in a patient with coronary heart disease: is mimicry possible?. Medical Alphabet, 2023, , 18-21.	0.2	0
191	Dynamics of global longitudinal strain of the left ventricular myocardium and blood biomarker levels in patients with rheumatoid arthritis treated with biologic disease-modifying antirheumatic drugs or Janus kinase inhibitors. Sovremennaya Revmatologiya, 2023, 17, 36-42.	0.5	0
192	Î²eta-adrenergic receptor reactivity of erythrocyte membranes in patients with left or right atrial dilatation against the background of atrial fibrillation. Bulletin of Siberian Medicine, 2023, 22, 61-67.	0.3	0
193	Relationship of Acylcarnitines to Myocardial Ischemic Remodeling and Clinical Manifestations in Chronic Heart Failure. Journal of Cardiovascular Development and Disease, 2023, 10, 438.	1.6	0
194	High-sensitivity C-reactive protein as a predictor, indicator of severity and prognostic indicator of chronic heart failure. , 2023, 20, 16-21.		0
195	Creation of registers as one of the mechanisms for improving medical care for patients with chronic heart failure. Problem state. Terapevticheskii Arkhiv, 2023, 95, 739-745.	0.8	0

#	Article	IF	Citations
196	Possibilities of instrumental determination of volemic status in patients with acute decompensation of chronic heart failure. Terapevticheskii Arkhiv, 2023, 95, 769-775.	0.8	0
197	Effect of dapagliflozin on the dynamics of magnetic resonance imaging in patients with heart failure and atrial fibrillation. Terapevticheskii Arkhiv, 2023, 95, 776-781.	0.8	0
198	Relationship between free circulating DNA levels, ejection fraction and brain natriuretic peptide levels in patients with chronic heart failure: prospective observational study. Cardiosomatics, 2023, 14, 167-175.	0.4	0
199	Influence of genetic characteristics of patients on systolic and diastolic function after acute myocardial infarction: a literature review. Russian Journal of Cardiology, 2023, 28, 5536.	1.4	0
200	Interim analysis of a prospective observational multicenter registry study of patients with chronic heart failure in the Russian Federation "PRIORITET-CHF": initial characteristics and treatment of the first included patients. Russian Journal of Cardiology, 2023, 28, 5593.	1.4	0
201	Analysis of the controlled essential hypertensionâ€™s pharmacotherapy in general practice. Russian Family Doctor, 2023, 27, 13-21.	0.1	0
202	Role of echocardiography in heart failure with preserved ejection fraction. Medical Visualization, 0, , .	0.4	0
203	The effect of mexidol as part of complex therapy on the perception of life in patients with heart failure. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2023, 16, 642.	0.3	0
204	Intravenous Cavutilide for Pharmacological Conversion of Paroxysmal and Persistent Atrial Fibrillation in Patients with Heart Failure. Journal of Cardiovascular Development and Disease, 2023, 10, 487.	1.6	0
205	Prevention of thrombotic complications in patients with AL amyloidosis. Oncogematologiya, 2023, 18, 225-232.	0.3	1
206	Prevalence of â€œhiddenâ€•forms of chronic heart failure. , 2023, 19, 457-468.	0.1	0
207	Decompensated heart failure: a reconceptualization in the light of updated consensus statement of the European Society of Cardiology. Russian Journal of Cardiology, 2023, 28, 5581.	1.4	0
208	Cost-effectiveness of valsartan+sakubitril, dapagliflosin and empagliflosin for prevention of cardiovascular death and reducing cardiovascular mortality within the State Program "Health Development" in patients with heart failure. Russian Journal of Cardiology, 2023, 28, 5711.	1.4	0
210	A clinical case of iron deficiency anemia in an elderly patient with a complicated cardiovascular history. Clinical Medicine and Pharmacology, 2023, 9, 2-5.	0.1	0
211	Clinical Case of Pulmonary Hypertension Secondary to Chronic Obstructive Pulmonary Disease in the Patient with History of Pulmonary Tuberculosis. Tuberculosis and Lung Diseases, 2023, 101, 64-68.	0.7	0
212	Full Reverse Left Ventricle Conteractility Function Remodeling and Recovery in Patient With Dilated Cardiomyopathy. Clinical Case. Kardiologiya, 2023, 63, 93-95.	0.7	0
213	Management of a patient with subacute tricuspid valve and pacemaker endocarditis with chronic thromboembolic pulmonary hypertension: a case report. Russian Journal of Cardiology, 2023, 28, 5501.	1.4	0
214	Compliance of the management of hospitalized patients with heart failure with the quality criteria for health care: data from the St. Petersburg registry. Russian Journal of Cardiology, 2023, 28, 5621.	1.4	0

#	Article	IF	Citations
215	Beta-blockers in chronic heart failure with preserved left ventricular ejection fraction: is deprescribing possible?. Rational Pharmacotherapy in Cardiology, 2023, 19, 607-613.	0.8	0
216	The register of patients suffering from heart failure in St. Petersburg â€persona-chfâ€: interim results. Vestnik of Russian Military Medical Academy, 2024, 25, 595-602.	0.3	0
217	BIOMARKERS OF HEART FAILURE IN PEDIATRIC PRACTICE. Complex Issues of Cardiovascular Diseases, 2023, 12, 149-162.	0.5	0
218	Diagnostic and clinical significance of cell free DNA levels in patients with chronic heart failure. Medical and Social Expert Evaluation and Rehabilitation, 2024, 26, 155-164.	0.2	0
219	Associations of the left ventricle myocardial deformation parametrs with cardiovascular risk in patients with an implanted cardioverter-defibrillator. Journal of Arrhythmology, 2024, 31, 39-46.	0.2	0
220	INFLUENCE OF REMOTE DIGITAL OBSERVATIONS ON QUALITY OF LIFE, COMPLIANCE, AND CLINICAL OUTCOMES IN PATIENTS WITH CHRONIC HEART FAILURE. Bio-Medical Engineering, 2024, 57, 311-315.	0.5	0
221	Pharmacogenetic predictors associated with reduced risk of secondary to enalapril cough. , 2024, 20, 109-116.		0
222	Comorbid conditions in patients with chronic heart failure (according to the registry of chronic) Tj ETQq1 1 0.784314 rgBT /Overlock	0.3	0
223	ÐÐ½Ð°Ð»Ð¸Ð· Ñƒ Ñ€Ð¾Ð²Ð½Ñ•ÑÐ²Ð¾Ð±Ð¾Ð´Ð½Ð¾Ð¹ Ñ†Ð¸Ñ€ÐºÑƒÐ»Ð¸Ñ€ÑƒÑŽÑ‰ÐµÐ¹ Ð”ÐÐš Ð¸ Ð¿ÐµÑ€ÐµÐ¼ÐµÐ½Ð½Ð¾Ð¹		
224	The severity of chronic heart failure and the parameters of daily blood pressure profile in patients with coronary heart disease. Exploration of Medicine, 0, , 101-111.	1.5	0
225	Long-Term Effects of Sacubitril/Valsartan After Chemotherapy for Breast Cancer in Patients With Chronic heart Failure. Innovative Medicine of Kuban, 2024, , 37-44.	0.2	0
226	The effectiveness of hardware CPAP therapy in heart failure with preserved left ventricular ejection fraction and obstructive sleep apnea syndrome. Terapevticheskii Arkhiv, 2024, 96, 36-41.	0.8	0
227	Whether to implant a defibrillator or not? The Possibility of Using the MADIT-ICD Benefit Score Calculator in Real Practice. Kardiologiya, 2024, 64, 27-33.	0.7	0
228	Inflammation and myocardial fibrosis: is there a relation with left bundle branch block. Terapevticheskii Arkhiv, 2024, 96, 22-28.	0.8	0
229	Prevalence of heart failure among hospitalized patient with T2D: results of a prospective observational multicenter study (CREDO). Diabetes Mellitus, 2024, 27, 4-14.	1.9	0